Recognition and degradation of myelin basic protein peptides by serum autoantibodies: Novel biomarker for multiple sclerosis

Journal of Immunology

Volumn 180, Issue 2, 2008, Pages 1258-1267

  Belogurov Jr , Alexey A ^a   Kurkova, Inna N ^a   Friboulet, Alain ^e   Thomas, Daniel ^e   Misikov, Viktor K ^d   Zakharova, Maria Yu ^a   Suchkov, Sergey V ^d   Kotov, Sergey V ^d   Alehin, Alexander I ^c   Avalle, Bérangère ^e   Souslova, Ekaterina A ^a   Morse III, Herbert C ^f   Gabibov, Alexander G ^a,b   Ponomarenko, Natalia A ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b INSTITUTE OF GENE BIOLOGY   (Russian Federation)

^c RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

^d M F VLADIMIRSKY MOSCOW REGIONAL RESEARCH CLINICAL INSTITUTE   (Russian Federation)

^e UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; EPITOPE; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; UNCLASSIFIED DRUG; AUTOANTIGEN; CATALYTIC ANTIBODY; PEPTIDE; PEPTIDE LIBRARY;

ADOLESCENT; ADULT; AGED; ANTIBODY AFFINITY; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CATALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN TISSUE; MULTIPLE SCLEROSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; AMINO ACID SEQUENCE; BLOOD; ENZYME SPECIFICITY; EPITOPE MAPPING; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ANTIBODIES, CATALYTIC; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; PEPTIDE LIBRARY; PEPTIDES; SUBSTRATE SPECIFICITY;

EID: 40449119704     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.2.1258     Document Type: Article

References (48)

1. Hafler, D. A. 2004. Multiple sclerosis. J. Clin. Invest. 113: 788-794.
2. Kornek, B., and H. Lassmann. 2003. Neuropathology of multiple sclerosis-new concepts. Brain Res. Bull. 61: 321-326.
3. Merkler, D., E. Horvath, W. Bruck, R. M. Zinkernagel, J. C. Del la Torre, and D. D. Pinschewer. 2006. "Viral deja vu" elicits organ-specific immune disease independent of reactivity to self. J. Clin. Invest. 116: 1254-1263.
4. Hohlfeld, R., and H. Wekerle. 2004. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. USA 101 (Suppl. 2): 14599-14606.
5. Klawiter, E. C., and A. H. Cross. 2007. B cells: no longer the nondominant arm of multiple sclerosis. Curr. Neurol. Neurosci. Rep. 7: 231-238.
6. Nikbin, B., M. M. Bonab, F. Khosravi, and F. Talebian. 2007. Role of B cells in pathogenesis of multiple sclerosis. Int. Rev. Neurobiol. 79: 13-42.
7. Genain, C. P., B. Cannella, S. L. Hauser, and C. S. Raine. 1999. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5: 170-175.
8. Tomassini, V., L. De Giglio, M. Reindl, P. Russo, I. Pestalozza, P. Pantano, T. Berger, and C. Pozzilli. 2007. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult. Scler. 13: 1086-1094.
9. Kuhle, J., R. L. Lindberg, A. Regeniter, M. Mehling, F. Hoffmann, M. Reindl, T. Berger, E. W. Radue, D. Leppert, and L. Kappos. 2007. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J. Neurol. 254: 160-168.
10. Berger, T., P. Rubner, F. Schautzer, R. Egg, H. Ulmer, I. Mayringer, E. Dilitz, F. Deisenhammer, and M. Reindl. 2003. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 349: 139-145.
11. Kuhle, J., C. Pohl, M. Mehling, G. Edan, M. S. Freedman, H. P. Hartung, C. H. Polman, D. H. Miller, X. Montalban, F. Barkhof, et al. 2007. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N. Engl. J. Med. 356: 371-378.
12. Miller, D. H. 2004. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 1: 284-294.
13. Sormani, M. P., and M. Filippi. 2007. Statistical issues related to the use of MRI data in multiple sclerosis. J. Neuroimaging 17 (Suppl. 1): 56S-59S.
14. Mattsson, N., S. Haghighi, O. Andersen, Y. Yao, L. Rosengren, K. Blennow, D. Pratico, and H. Zetterberg. 2007. Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neurosci. Lett. 414: 233-236.
15. Waubant, E. 2006. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis. Markers 22: 235-244.
16. Charil, A., T. A. Yousry, M. Rovaris, F. Barkhof, N. De Stefano, F. Fazekas, D. H. Miller, X. Montalban, J. H. Simon, C. Polman, and M. Filippi. 2006. MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation." Lancet Neurol. 5: 841-852.
17. Lacroix-Desmazes, S., B. Wootla, S. Delignat, S. Dasgupta, V. Nagaraja, M. D. Kazatchkine, and S. V. Kaveri. 2006. Pathophysiology of catalytic antibodies. Immunol. Lett. 103: 3-7.
18. Paul, S., D. J. Volle, C. M. Beach, D. R. Johnson, M. J. Powell, and R. J. Massey. 1989. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 244: 1158-1162.
19. Shuster, A. M., G. V. Gololobov, O. A. Kvashuk, A. E. Bogomolova, I. V. Smirnov, and A. G. Gabibov. 1992. DNA hydrolyzing autoantibodies. Science 256: 665-667.
20. Gololobov, G. V., E. A. Chernova, D. V. Schourov, I. V. Smirnov, I. A. Kudelina, and A. G. Gabibov. 1995. Cleavage of supercoiled plasmid DNA by autoantibody Fab fragment: application of the flow linear dichroism technique. Proc. Natl. Acad. Sci. USA 92: 254-257.
21. Lacroix-Desmazes, S., J. Bayry, N. Misra, M. P. Horn, S. Villard, A. Pashov, N. Stieltjes, R. d'Oiron, J. M. Saint-Remy, J. Hoebeke, et al. 2002. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N. Engl. J. Med. 346: 662-667.
22. Paul, S., L. Li, R. Kalaga, J. O'Dell, R. E. Dannenbring, Jr., S. Swindells, S. Hinrichs, P. Caturegli, and N. R. Rose. 1997. Characterization of thyroglobulin-directed and polyreactive catalytic antibodies in autoimmune disease. J. Immunol. 159: 1530-1536.
23. Pagetta, A., E. Tramentozzi, L. Corbetti, M. Frasson, A. M. Brunati, and P. Finotti. 2007. Characterization of immune complexes of idiotypic catalytic and anti-idiotypic inhibitory antibodies in plasma of type 1 diabetic subjects. Mol. Immunol. 44: 2870-2883.
24. Ponomarenko, N. A., O. M. Durova, I. I. Vorobiev, A. A. Belogurov, Jr., I. N. Kurkova, A. G. Petrenko, G. B. Telegin, S. V. Suchkov, S. L. Kiselev, M. A. Lagarkova, et al. 2006. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc. Natl. Acad. Sci. USA 103: 281-286.
25. Ponomarenko, N. A., O. M. Durova, I. I. Vorobiev, A. A. Belogurov, G. B. Telegin, S. V. Suchkov, V. K. Misikov, H. C. Morse, III, and A. G. Gabibov. 2006. Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunol. Lett. 103: 45-50.
26. Ponomarenko, N. A., O. M. Durova, I. I. Vorobiev, E. S. Aleksandrova, G. B. Telegin, O. G. Chamborant, L. L. Sidorik, S. V. Suchkov, Z. S. Alekberova, N. V. Gnuchev, and A. G. Gabibov. 2002. Catalytic antibodies in clinical and experimental pathology: human and mouse models. J. Immunol. Methods 269: 197-211.
27. Polosukhina, D. I., T. G. Kanyshkova, B. M. Doronin, O. B. Tyshkevich, V. N. Buneva, A. N. Boiko, E. I. Gusev, O. O. Favorova, and G. A. Nevinsky. 2004. Hydrolysis of myelin basic protein by polyclonal catalytic IgGs from the sera of patients with multiple sclerosis. J. Cell. Mol. Med. 8: 359-368.
28. Fridkis-Hareli, M., D. Teitelbaum, E. Gurevich, I. Pecht, C. Brautbar, O. J. Kwon, T. Brenner, R. Arnon, and M. Sela. 1994. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells: specificity and promiscuity. Proc. Natl. Acad. Sci. USA 91: 4872-4876.
29. Husted, C. 2006. Structural insight into the role of myelin basic protein in multiple sclerosis. Proc. Natl. Acad. Sci. USA 103: 4339-4340.
30. Poser, C. M., and V. V. Brinar. 2001. Diagnostic criteria for multiple sclerosis. Clin. Neurol. Neurosurg. 103: 1-11.
31. Miller, D., and W. J. Karpus. 1996. Experimental autoimmune encephalomyelitis in the mouse. In Current Protocols in Immunology. J. E. Coligan, ed. Wiley, New York, p. S19.
32. Pelidou, S. H., S. Giannopoulos, S. Tzavidi, N. Tsifetaki, G. Kitsos, D. Stefanou, V. Kostadima, A. A. Drosos, and A. P. Kyritsis. 2007. Neurological manifestations of connective tissue diseases mimicking multiple sclerosis. Rheumatol. Int. 28: 15-20.
33. D'Souza, C. A., and M. A. Moscarello. 2006. Differences in susceptibility of MBP charge isomers to digestion by stromelysin-1 (MMP-3) and release of an immunodominant epitope. Neurochem. Res. 31: 1045-1054.
34. D'Souza, C. A., D. D. Wood, Y. M. She, and M. A. Moscarello. 2005. Autocatalytic cleavage of myelin basic protein: an alternative to molecular mimicry. Biochemistry 44: 12905-12913.
35. Medveczky, P., J. Antal, A. Patthy, K. Kekesi, G. Juhasz, L. Szilagyi, and L. Graf. 2006. Myelin basic protein, an autoantigen in multiple sclerosis, is selectively processed by human trypsin 4. FEBS Lett. 580: 545-552.
36. Musse, A. A., J. M. Boggs, and G. Harauz. 2006. Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc. Natl. Acad. Sci. USA 103: 4422-4427.
37. Pritzker, L. B., S. Joshi, J. J. Gowan, G. Harauz, and M. A. Moscarello. 2000. Deimination of myelin basic protein: I. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry 39: 5374-5381.
38. Lolli, F., B. Mulinacci, A. Carotenuto, B. Bonetti, G. Sabatino, B. Mazzanti, A. M. D'Ursi, E. Novellino, M. Pazzagli, L. Lovato, et al. 2005. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proc. Natl. Acad. Sci. USA 102: 10273-10278.
39. Doyle, H. A., and M. J. Mamula. 2001. Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol. 22: 443-449.
40. Hallpike, J. F., and C. W. Adams. 1969. Proteolysis and myelin breakdown: a review of recent histochemical and biochemical studies. Histochem. J. 1: 559-578.
41. Wentworth, P., Jr., L. H. Jones, A. D. Wentworth, X. Zhu, N. A. Larsen, I. A. Wilson, X. Xu, W. A. Goddard, III, K. D. Janda, A. Eschenmoser, and R. A. Lerner. 2001. Antibody catalysis of the oxidation of water. Science 293: 1806-1811.
42. Wentworth, P., Jr., and K. D. Janda. 2001. Catalytic antibodies: structure and function. Cell Biochem. Biophys. 35: 63-87.
43. Matsuura, K., and H. Sinohara. 1996. Catalytic cleavage of vasopressin by human Bence Jones proteins at the arginylglycinamide bond. Biol. Chem. 377: 587-589.
44. Lacroix-Desmazes, S., J. Bayry, S. V. Kaveri, D. Hayon-Sonsino, N. Thorenoor, J. Charpentier, C. E. Luyt, J. P. Mira, V. Nagaraja, M. D. Kazatchkine, et al. 2005. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc. Natl. Acad. Sci. USA 102: 4109-4113.
45. Warren, K. G., I. Catz, L. Z. Ferenczi, and M. J. Krantz. 2006. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur. J. Neurol. 13: 887-895.
46. Cao, L., R. Goodin, D. Wood, M. A. Moscarello, and J. N. Whitaker. 1999. Rapid release and unusual stability of immunodominant peptide 45-89 from citrullinated myelin basic protein. Biochemistry 38: 6157-6163.
47. Gabibov, A. G., G. V. Gololobov, O. I. Makarevich, D. V. Schourov, E. A. Chernova, and R. P. Yadav. 1994. DNA-hydrolyzing autoantibodies. Appl. Biochem. Biotechnol. 47: 293-303.
48. Burster, T., A. Beck, S. Poeschel, A. Oren, D. Baechle, M. Reich, O. Roetzschke, K. Falk, B. O. Boehm, S. Youssef, et al. 2007. Interferon-γ regulates cathepsin G activity in microglia-derived lysosomes and controls the proteolytic processing of myelin basic protein in vitro. Immunology 121: 82-93.